Thieler Law Corp advises investors with losses exceeding $100,000 of the March 11, 2019 lead plaintiff deadline in a class action lawsuit filed against AxoGen Inc (NASDAQ: AXGN) (“AxoGen” or “the Company”). The suit is pending in the U.S. District Court for the Middle District of Florida and investors, who purchased AxoGen common stock in connection with the Company’s November 2017 Initial Public Offering (“IPO”) or between August 7, 2017 and December 18, 2018, have until March 11, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased AxoGen Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that the Company aggressively increased prices to mask lower sales; the Company’s pricing alienated customers and threatened the Company’s future growth; ambulatory surgery centers form a significant part of the market for the Company’s products; such centers were especially sensitive to price increases; the Company was dependent on a small number of surgeons whom the Company paid to generate sales; the Company’s consignment model for inventory was reasonably likely to lead to channel stuffing; the Company offered purchase incentives to sales representatives to encourage channel stuffing; the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; the Company’s key operating metrics, such as number of active accounts, were overstated; and as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On December 18, 2018, a report by Seligman Investments revealed, among other things, that former employees allege channel stuffing and backdating of revenue, that the number of active accounts may be overstated by a factor of ten, and that aggressive annual price increases had driven the Company’s revenue growth.

Following this news, NASDAQ: AXGN fell $6.17 per share, nearly 22%, to close at $21.36 per share on December 18.

If you were negatively impacted by your investment in AxoGen Inc securities in connection with the Company’s November 2017 Initial Public Offering (“IPO”) or between August 7, 2017 and December 18, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185